Phase II trial of ivacaftor in combination with lumacaftor in patients aged ≥18 years with cystic fibrosis and one copy (heterozygous) of the F508del mutation on one allele and a second mutation that is not expected to respond to either ivacaftor or lumacaftor alone.

Trial Profile

Phase II trial of ivacaftor in combination with lumacaftor in patients aged ≥18 years with cystic fibrosis and one copy (heterozygous) of the F508del mutation on one allele and a second mutation that is not expected to respond to either ivacaftor or lumacaftor alone.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2013

At a glance

  • Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 21 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top